Pharming Group (PHGN) Stock Statistics & Valuation Metrics
Total Valuation
Pharming Group has a market cap or net worth of EUR 771.13M. The enterprise value is EUR 596.37M.
- Market Cap
- EUR 771.13M
- Enterprise Value
- EUR 596.37M
Share Statistics
Pharming Group has 707,781,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 707,781,250
- Owned by Insiders
- ―
- Owned by Institutions
- 4.38%
Financial Efficiency
Pharming Group’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.05%.
- Return on Equity (ROE)
- 0.01
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 1.05%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 924.16K
- Profits Per Employee
- 7,290.499
- Employee Count
- 407
- Asset Turnover
- 0.75
- Inventory Turnover
- 0.70
Valuation Ratios
The current PE Ratio of Pharming Group is 35.67. Pharming Group’s PEG ratio is 0.00.
- PE Ratio
- 35.67
- PS Ratio
- 2.29
- PB Ratio
- 3.10
- Price to FCF
- 28.93
- Price to Operating Cash Flow
- 28.13
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Pharming Group had revenue of 376.13M and earned 2.97M in profits. Earnings per share was 0.00.
- Revenue
- 376.13M
- Gross Profit
- 330.63M
- Operating Income
- 20.88M
- Pretax Income
- 12.85M
- Net Income
- 2.97M
- EBITDA
- 34.78M
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was 31.59M and capital expenditures -872,773, giving a free cash flow of 30.72M billion.
- Operating Cash Flow
- 31.59M
- Free Cash Flow
- 30.72M
- Free Cash Flow per Share
- 0.04
Dividends & Yields
Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.45%
- Earnings Yield
- 2.74%
Stock Price Statistics
- Beta
- 0.47
- 52-Week Price Change
- -2.28%
- 50-Day Moving Average
- 0.94
- 200-Day Moving Average
- 1.18
- Relative Strength Index (RSI)
- 71.66
- Average Volume (3m)
- 10.24K
Important Dates
Pharming Group upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Pharming Group as a current ratio of 2.59, with Debt / Equity ratio of 41.79%
- Current Ratio
- 2.59
- Quick Ratio
- 2.03
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- -0.87
- Interest Coverage Ratio
- 1.95
Taxes
In the past 12 months, Pharming Group has paid 10.31M in taxes.
- Income Tax
- 10.31M
- Effective Tax Rate
- 0.80
Enterprise Valuation
Pharming Group EV to EBITDA ratio is 18.98, with an EV/FCF ratio of 26.54.
- EV to Sales
- 2.10
- EV to EBITDA
- 18.98
- EV to Free Cash Flow
- 26.54
- EV to Operating Cash Flow
- 25.81
Balance Sheet
Pharming Group has EUR 186.42M in cash and marketable securities with EUR 112.61M in debt, giving a net cash position of EUR 73.80M billion.
- Cash & Marketable Securities
- EUR 186.42M
- Total Debt
- EUR 112.61M
- Net Cash
- EUR 73.80M
- Net Cash Per Share
- EUR 0.10
- Tangible Book Value Per Share
- EUR 0.40
Margins
Gross margin is 84.34%, with operating margin of 6.89%, and net profit margin of 6.30%.
- Gross Margin
- 84.34%
- Operating Margin
- 6.89%
- Pretax Margin
- 8.93%
- Net Profit Margin
- 6.30%
- EBITDA Margin
- 11.09%
- EBIT Margin
- 7.96%
Analyst Forecast
The average price target for Pharming Group is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 1.73%
- EPS Growth Forecast
- ―
